Biologically active antibodies recognizing a cell surface molecule selectively expressed on living mouse natural type one (i) interferon producing cells
OwnerAmanda L. Blasius, Marco Colonna +1inventors
InventorsAmanda L. Blasius, Marco Colonna, Marina Cella
Life of this patent
Estimating the term…
Abstract
An isolated and characterized monoclonal antibody (“440c”) prepared by immunizing Wistar/CRL rats subcutaneously with purified rat bone marrow IPC, fusing popliteal lymph nodes of the rats with SP2/0 myeloma spleen cells and differentially selecting for hybridome supernatants that successfully stain bone marrow derived IPC and fractions thereof using CD11c+ spleen cells and, differentially selecting for hybridoma supernatants from the CD11c+ spleen cells that successfully stain only CD 11 c+/Ly6c+/CD 11 b−/B220+ splenocytes to provide the monoclonal antibody.
Claims21
1-30. (canceled)
A monoclonal antibody that preferentially binds to a cell surface molecule of an IPC, wherein the cell surface molecule regulates secretion of IFN-α.
A method for determining whether IPCs are associated with an inflammatory infection or disease comprising:
- measuring an amount of Type I interferons in serum taken from a murine having the inflammatory infection or disease;
- administering to the murine a pharmacologically effective amount of a monoclonal antibody that preferentially binds to a cell surface molecule of an IPC, wherein the cell surface molecule regulates secretion of IFN-α,
- measuring an amount of Type I interferons in serum taken from the murine after administration of the monoclonal antibody;
- and
- comparing the amount of Type I interferons measured in the serum taken from the murine before administration of the monoclonal antibody to the amount of Type I interferons measured in the serum taken from the murine after administration of the monoclonal antibody.
A method for treating at least one symptom of an inflammatory response in a subject in need thereof the method comprises administering a pharmacologically effective amount of 440c mAb to alleviate the at least one inflammatory symptom.
Dependencies are inferred from the claim text.